EC Healthcare Collaborates with New Horizon Health to form Strategic Partnership To Jointly Launch CerviClear in Hong Kong
HONG KONG, Mar 24, 2023 - (ACN Newswire) - EC Healthcare (2138.HK) and New Horizon Health (6606.HK) host ceremony today to form an exclusive strategic partnership. Both parties will consolidate the resources to empower the launching, distribution, and promotion of CerviClear in Hong Kong. It is expected this home-use cancer screening product will help to increase the awareness penetration of Cervical cancer prevention, and achieve better prevention efficacy. Under the Partnership, EC Healthcare is the exclusive partner of New Horizon Health.
| Left to right: Mr. ZHENG Weixian Senior Director of Operation management, New Horizon Health, Dr. Rita Shih Head of International R&D Center, New Horizon Health, Mr. Li Yan Vice President, New Horizon Health, Mr. Zhu YeQing Chairman and CEO, New Horizon Health, Mr. Leslie LU Executive Director and Co-Chief Executive Officer, EC Healthcare,Dr. Eric CHU Chief Business Officer, EC Healthcare, Dr. Julie CHOW Chief Proposition Officer (Healthcare), EC Healthcare |
Cervical cancer is a common malignant tumor for women. The morbidity and mortality have been rising in recent years, with a notable trend of rejuvenation. Cervical cancer is also the only cancer with evident cause and can be eliminated through early intervention. Developed by New Horizon Health, CerviClear is the first Urine-based HPV Detection and Cervical Cancer Screening Test in the world . It is the only product comprehensively covering all 14 high-risk HPV virus and achieves non-invasive home-based urine self-sampling. The product has already obtained a CE Mark, and is qualified for launching in Hong Kong and the Greater Bay Area.
Mr. Leslie Lu, Executive Director and Co-CEO of EC Healthcare said, "We are glad to partner with New Horizon Health, a leading cancer screening company. The Group treasures strategic cooperation with upstream partners in the pharmaceutical field as the core strategy. Through collaboration with partners in biotech and pharmaceutical industry, the Group will further improve the preventive medicine market influence and further consolidate its industry leading position. This Partnership enables the Group to further diversify its service product mix by leveraging vaccination, health check and multiple medical specialties services to complete the one-stop ecosystem. We believe the collaboration will also accelerate the Group to achieve vertical integration of the industry value chain."
Mr. Zhu Yeqing, Executive Director and CEO of New Horizon Health said: "The effective way to promote the prevention of high-risk cancer is to provide convenient, reliable and compliant innovative screening products. CerviClear is the first product in the world that achieves urine self-sampling. Compared with the clinical examination, patients no longer needs to visit a hospital and the sampling procedure is non-invasive and painless. It is expected to significantly lower the time cost and pressure level for patients. EC Healthcare is the leading healthcare services provider in both Hong Kong and the Greater Bay Area. We are glad to partner with EC Healthcare and believe the partnership becomes a milestone for our pipeline and innovation commercialization."
About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.
The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.
*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021
About New Horizon Health Founded in 2015, New Horizon Health is a pioneer and leader in China's cancer screening market, focusing on early home screening of high-incidence cancers, aiming to promote innovation in cancer screening technology and accelerate the popularity of cancer screening technology in China. On February 18, 2021, New Horizon Health was successfully listed on the SEHK with stock code 6606.HK, which became "the first listed Chinese cancer early screening company".
New Horizon Health has three marketed products. ColoClear, Pupu Tube and UU Tube have all been approved by the National Medical Products Administration of China and are officially commercialized. ColoClear is the only cancer screening product approved by the National Medical Products Administration of China for people aged 40-74 who are at high risk of colorectal cancer. UU Tube is the only consumer self-test product for Helicobacter pylori approved by the National Medical Products Administration of China. Pupu Tube is the first FIT at-home self-test device approved in China. In addition, the Company has three pipelines of products in development for liver cancer (LiverClear), cervical cancer (CerviClear ) and nasopharyngeal cancer screening. The Company has global rights to all of its marketed and pipeline products.
New Horizon Health works extensively with hundreds of hospitals, health check-ups, insurance companies, pharmacies and online channels. The Company has a class 100,000 clean production workshop that meets ISO13485 and ISO9001 international certification standards. The third parties medical testing laboratories in Beijing, Hangzhou and Guangzhou have been certified by international quality standards and the local health care commission and issued licenses to practice, with an annual testing capacity of 2 million people.
Source: EC Healthcare Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System Mar 28, 2024 16:45 JST
| Mitsubishi Logisnext Completes Demonstration of Automated Truck Loading, Leading to Start of Actual Operations in Japan Mar 28, 2024 13:52 JST
| Toyota Releases Sales, Production, and Export Results for February 2024 Mar 28, 2024 13:35 JST
| TANAKA to Install 500 kW Fuel Cell System to Promote the Use of Hydrogen Energy at Production Plants Mar 28, 2024 03:00 JST
| PEVE to change name to TOYOTA BATTERY Co., Ltd. and produce batteries for a wide range of electric vehicles Mar 27, 2024 15:13 JST
| NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System Mar 27, 2024 15:00 JST
| TANAKA Holdings Announces Green Loan Financing for Construction of New Head Office Building Mar 27, 2024 03:00 JST
| JFE Steel and Hitachi Jointly Started Providing Solutions for the Steel Industry Mar 26, 2024 19:04 JST
| La Banque Postale and JCB join forces to elevate payments experience for travellers in France Mar 26, 2024 15:00 JST
| Fujitsu Tech Leverages AI and Underwater Drone Data for 'Ocean Digital Twin' Mar 26, 2024 10:24 JST
| NEC develops marketing strategy planning & effectiveness simulation technology using generative AI Mar 25, 2024 10:08 JST
| Toyota to Open New Tokyo Head Office in Shinagawa in FY2030 Mar 22, 2024 16:15 JST
| Hitachi Selected as CDP Supplier Engagement Leader for the Third Consecutive Year Mar 22, 2024 16:04 JST
| Mitsubishi Motors Celebrates Production of 100,000th fully electric minivehicle Mar 22, 2024 15:34 JST
| JCB and AEON Credit Service Indonesia Launch the AEON JCB Precious Card Mar 22, 2024 15:00 JST
| JCB Issues White Paper on Calculating CO2 Emissions by Payment Method in Japan Mar 22, 2024 12:00 JST
| NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber Mar 22, 2024 08:38 JST
| Lifenet and Eisai Co-Develop Dementia Insurance "be" Mar 21, 2024 17:36 JST
| Toyota: Clarification of the Roles of and Expectations for Outside Executives, Revision of the Independence Assessment Criteria, and the Changes to Members of the Board of Directors and the Audit and Supervisory Board Members following the 120th Ordinary General Shareholders' Meeting Mar 21, 2024 16:47 JST
| Sales of Evolved GR Yaris to Start in April, While Purchasing Lotteries for WRC Driver-supervised Special Editions Start Today Mar 21, 2024 16:31 JST
|
More Latest Release >>
|